Emergency restrictions on sale and supply of puberty blockers

The General Pharmaceutical Council (GPhC) has alerted pharmacists, pharmacy technicians, and pharmacy owners via email regarding new emergency legislation
governing the prescribing and supply of puberty-suppressing hormones, commonly known as ‘puberty blockers’, for children and young people under 18 in England,
Wales, and Scotland.

The regulations apply to gonadotropin-releasing hormone (GnRH) analogues, used to suppress puberty as part of treating gender incongruence or gender dysphoria in
individuals under 18.

Effective from 3 June 2024, new private prescriptions for GnRH analogues from prescribers in the European Economic Area (EEA) or Switzerland who are not UK
registered are banned from being dispensed in Great Britain for patients under 18.

The emergency ban on these medicines will remain in effect until September 3, 2024, the Department of Health and Social Care (DHSC) announced on 29 May, stating
that the action has been taken to address risks to “patient safety.”